In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...